GSK’s $2.2 Billion Acquisition of RAPT Therapeutics
Deal Overview
Acquirer: GSK plc
Target: RAPT Therapeutics, Inc.
Total transaction size: ~$2.2 billion (all-cash)
Price per share: $58.00 per share
Structure: All-cash tender offer followed by second-step merger under Delaware law
Public announcement date: 20 January 2026
Expected closing: Q1 2026 (Subject to regulatory approval and majority tender condition)
On 20 January 2026, GSK announced it had agreed to acquire US-based RAPT Therapeutics for approximately $2.2 billion in cash. The deal focuses mainly on RAPT’s lead drug candidate, ozureprubart, which is a long-acting anti-IgE antibody currently in Phase IIb trials for food allergy.
GSK presented the acquisition as a method to strengthen its respiratory, immunology, and inflammation pipeline, specifically in allergy treatments. The transaction is a tender offer, which allows GSK to buy shares directly from shareholders before completing a follow-on merger. Legally, the main considerations are US antitrust approval under the Hart–Scott–Rodino (HSR) Act and the broader risks, potentially regulatory and clinical, involved in acquiring a mid-stage drug candidate.
Company Details: Acquirer - GSK
GSK was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000 and has since become one of the world’s largest pharmaceutical companies. At the time of the deal, GSK was led by CEO Luke Miels and had a market capitalisation of over £60 billion. GSK works across vaccines and specialty medicines, with a strategic focus on respiratory diseases, immunology, and inflammation. In recent years, GSK has concentrated its research and development on high-value biologic medicines, particularly in areas where it has commercial expertise. This includes allergy and respiratory treatments, where it has relationships with clinicians and healthcare providers.
Like many large pharmaceutical companies, GSK operates in an industry shaped by patent expirations, rising development costs, and intensifying competition in biologic medicines. These pressures have encouraged many firms to expand their pipelines through partnerships and acquisitions of smaller biotechnology companies developing promising clinical-stage therapies.
Company Details: Target – RAPT Therapeutics
RAPT Therapeutics was founded in 2015, originally known as FLX Bio, and operated as a clinical-stage biotech company focused on immune and inflammatory diseases. When it was acquired, it was led by CEO Brian Wong. RAPT’s main asset was ozureprubart (RPT904), a long-acting anti-IgE antibody, which was developed for food allergy prevention. The drug was in Phase IIb clinical trials when the deal was announced and represented the central value driver within the company’s pipeline.
Prior to the acquisition, RAPT had experienced difficulties. In 2024, the US Food and Drug Administration (FDA) placed clinical holds on another drug candidate, zelnecirnon, due to safety concerns, after which the programme was discontinued. As a result, the company became heavily dependent on ozureprubart as its principal development asset.
The Acquisition
GSK and RAPT signed the merger agreement on 19 January 2026, and it was publicly announced on 20 January 2026. The transaction is structured as an all-cash tender offer through a GSK subsidiary, which allows the company to purchase shares directly from RAPT shareholders before completing a second-step merger to acquire the remaining outstanding shares. If a majority of RAPT’s shares are tendered, the follow-on merger will proceed under Section 251(h) of the Delaware General Corporation Law. This will enable GSK to obtain full ownership without a separate shareholder vote. The deal is expected to close in Q1 2026, subject to customary closing conditions, which include satisfaction of the majority tender requirement and the expiry or termination of the waiting period under the HSR Act.
Strategically, the acquisition reflects GSK’s effort to strengthen its respiratory, immunology, and inflammation portfolio through targeted pipeline expansion. RAPT’s lead asset, ozureprubart, targets IgE, a well-validated pathway in allergic disease, and is being developed as a long-acting therapy for food allergy. GSK emphasised that ozureprubart is meant for 12-week dosing, which could offer a significant convenience advantage over existing anti-IgE therapies that typically require injections every two to four weeks. If successful, this could create an advantage in convenience and patient adherence.
For RAPT, the deal offers access to the financial resources and global development infrastructure needed to progress late-stage clinical trials and eventual commercialisation, which it previously lacked as a smaller biotechnology company. After setbacks in its previous programme, RAPT had become heavily reliant on ozureprubart. The acquisition provides shareholders with liquidity at a premium and allows ozureprubart to develop within a larger pharmaceutical platform. After the acquisition, ozureprubart is expected to be in GSK’s Respiratory, Immunology, and Inflammation division. Currently, the detailed integration has not been publicly disclosed. However, considering the focus is on a single asset, the integration will likely focus on transferring clinical development oversight and aligning the programme with GSK’s global regulatory and commercial teams. The trial data for Phase IIb is expected in 2027. If results are positive, there will likely be progression into Phase III. In the near term, integration will therefore focus on clinical execution and regulatory preparation instead of immediate commercial rollout.
The transaction is structured in a two-step process:
A cash tender offer to RAPT shareholders.
A second-step merger under Section 251(h) of the Delaware General Corporation Law.
This allows GSK to acquire control once a majority of the shares are tendered, without requiring a separate shareholder vote. It is commonly used in US public company acquisitions since it results in faster transactions and more certainty compared to a traditional merger vote. RAPT’s board also filed the required Schedule 14D-9 with the Securities and Exchange Commission (SEC), which recommended that shareholders tender their shares.
The more significant legal and regulatory risk seems to be in the clinical development pathway. Ozureprubart is currently in Phase IIb trials. However, progression to Phase III is not guaranteed. Regulatory authorities, such as the FDA, may require additional data, raise safety concerns, or delay approval. Therefore, this is a pipeline acquisition. This means the value of the acquisition depends heavily on the future success of regulatory approval rather than existing revenues.
Antitrust review under HSR will likely not block the deal. However, timing could delay closing if regulators want additional information. The main financial risk is clinical. If the Phase IIb data is not strong or there are safety concerns, the projected value of the acquisition could fall significantly. However, strong data would materially increase the strategic value of the asset. This transaction is more of a calculated development-stage risk instead of a risk based on competition regulations.
Healthcare regulators worldwide have become more attentive to acquisitions in markets driven by innovation, especially where dominant firms acquire early-stage pipeline assets. However, here, the competition issues appear to be limited, and GSK is not acquiring a direct competitor. The main risk here is executional. Success depends on clinical trial outcomes, regulatory approvals, and GSK’s ability to integrate and progress the programme efficiently.
Legal Contentions & Regulatory Impact
The transaction is subject to review under the HSR Act, which requires parties to certain large US transactions to notify the Federal Trade Commission (FTC) and Department of Justice (DOJ) and observe a waiting period before closing. Expiry or early termination of the HSR waiting period is an explicit closing condition. This is standard for US public company acquisitions of this size. Here, the competitive overlap is limited. GSK is acquiring a clinical-stage asset, not a competitor in the same product market. Thus, any significant antitrust issues appear unlikely to be raised.
Industry Impact
The acquisition of RAPT should be understood in the context of the evolution of the food allergy treatment market. For many years, management of food allergy has relied on avoidance and emergency treatment. In February 2024, this changed when the FDA approved Xolair (omalizumab) for IgE-mediated food allergy. This was the first biologic therapy specifically indicated to reduce allergic reactions from accidental exposure. The approval of Xolair effectively validated IgE as a therapeutic target in food allergy and showed a willingness for regulators to approve preventative biologics. It also made a commercial benchmark. However, Xolair requires injections every two to four weeks, which can be burdensome for some paediatric patients. Ozureprubart is being developed as a long-acting anti-IgE therapy with a 12-week dosing regimen. If clinical results support this, it could mean a large convenience advantage.
At the same time, food allergy prevalence has been rising worldwide, particularly among children, contributing to a growing demand for preventative therapies. Increased diagnosis rates and higher payer acceptance of biologic treatments have also strengthened the commercial case for new treatments in this area. Even though the market is still developing, the approval of Xolair has reduced uncertainty surrounding regulations and improved the commercial argument for further innovation in this sector. Pricing and reimbursement will be important here. In the US, biologics face a lot of scrutiny from payers regarding their cost-effectiveness and comparative benefit. A 12-week dosing interval could improve adherence and potentially reduce administration costs over time, which may improve reimbursement arguments. In the UK, adoption would depend on the NHS and NICE assessment of the clinical benefit and cost-effectiveness within existing allergy treatments.
House View
The acquisition can best be understood as a platform durability bet. If ozureprubart shows strong efficacy and safety in Phase IIb and progresses to Phase III, its longer dosing interval could differentiate it from other anti-IgE therapies. For patients, particularly children, it could reduce injections from monthly to quarterly. This would improve adherence and real-world use. In that situation, GSK would secure a strategically durable asset within a growing allergy market. However, this remains a development-stage programme. The key inflection point will be the Phase IIb prestIgE readout expected in 2027. Trial design, patient response, and safety outcomes will decide whether the drug can actually compete with or improve upon existing standards of care.
Safety expectations within the anti-IgE class are already well established, meaning that any unexpected adverse effects could significantly undermine the programme’s value. Execution will therefore be crucial. GSK must successfully integrate the programme, maintain clinical development, and prepare for potential paediatric-focused regulatory review. Ultimately, the transaction is less a regulatory gamble than a clinical execution bet. If the dosing advantage results in real-world benefits, GSK strengthens its immunology franchise with a differentiated asset. If not, the acquisition represents paid optionality in a competitive and scientifically uncertain market.
References
GlaxoSmithKline plc. (2026). GSK enters agreement to acquire RAPT Therapeutics. [online, press release]. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/
GlaxoSmithKline plc. (2026). Agreement to acquire RAPT Therapeutics. [online, presentation]. Available at: https://www.gsk.com/media/paddln2v/agreement-to-acquire-rapt-therapeutics-slides.pdf
The Guardian. (2026). GSK to buy food allergy drug maker RAPT in $2.2bn deal. [online] Available at: https://www.theguardian.com/business/2026/jan/20/gsk-buy-food-allergy-drug-maker-rapt-us-biotech
Reuters. (2026). GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug. [online]. Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-rapt-therapeutics-22-billion-2026-01-20/
U.S. Securities and Exchange Commission. (2026). Schedule 14D-9 – RAPT Therapeutics, Inc. [online]. Available at: https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/d12800d8k.htm
U.S. Food and Drug Administration. (2024). FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure. [online]. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental
Federal Trade Commission. (n.d.). Premerger Notification Program (Hart–Scott–Rodino Act). [online]. Available at: https://www.ftc.gov/enforcement/premerger-notification-program
Fierce Biotech. (2026). GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair. [online]. Available at: https://www.fiercebiotech.com/biotech/gsk-pays-22b-buy-rapt-its-phase-2-stage-food-allergy-challenger-xolair
Evaluate Ltd. (2025). 2025 Preview: What does the year ahead hold for pharma?. [online]. Available at: https://www.evaluate.com/thought-leadership/2025-preview/